These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30201735)

  • 1. TLR Stimulation during T-cell Activation Lowers PD-1 Expression on CD8
    Zahm CD; Colluru VT; McIlwain SJ; Ong IM; McNeel DG
    Cancer Immunol Res; 2018 Nov; 6(11):1364-1374. PubMed ID: 30201735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toll-like receptor agonist combinations augment mouse T-cell anti-tumor immunity via IL-12- and interferon ß-mediated suppression of immune checkpoint receptor expression.
    Jeon D; McNeel DG
    Oncoimmunology; 2022; 11(1):2054758. PubMed ID: 35340661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-1 Blockade and CD27 Stimulation Activate Distinct Transcriptional Programs That Synergize for CD8
    Buchan SL; Fallatah M; Thirdborough SM; Taraban VY; Rogel A; Thomas LJ; Penfold CA; He LZ; Curran MA; Keler T; Al-Shamkhani A
    Clin Cancer Res; 2018 May; 24(10):2383-2394. PubMed ID: 29514845
    [No Abstract]   [Full Text] [Related]  

  • 4. TLR1/2 ligand-stimulated mouse liver endothelial cells secrete IL-12 and trigger CD8+ T cell immunity in vitro.
    Liu J; Jiang M; Ma Z; Dietze KK; Zelinskyy G; Yang D; Dittmer U; Schlaak JF; Roggendorf M; Lu M
    J Immunol; 2013 Dec; 191(12):6178-90. PubMed ID: 24227786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of NKT Cells in an Anti-PD-1-Resistant Tumor Model Enhances Antitumor Immunity by Reinvigorating Exhausted CD8 T Cells.
    Bae EA; Seo H; Kim BS; Choi J; Jeon I; Shin KS; Koh CH; Song B; Kim IK; Min BS; Han YD; Shin SJ; Kang CY
    Cancer Res; 2018 Sep; 78(18):5315-5326. PubMed ID: 30012672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A combined carrier-adjuvant system of peptide nanofibers and toll-like receptor agonists potentiates robust CD8+ T cell responses.
    Rudra JS; Banasik BN; Milligan GN
    Vaccine; 2018 Jan; 36(4):438-441. PubMed ID: 29248267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors.
    Duraiswamy J; Kaluza KM; Freeman GJ; Coukos G
    Cancer Res; 2013 Jun; 73(12):3591-603. PubMed ID: 23633484
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN.
    Ahonen CL; Doxsee CL; McGurran SM; Riter TR; Wade WF; Barth RJ; Vasilakos JP; Noelle RJ; Kedl RM
    J Exp Med; 2004 Mar; 199(6):775-84. PubMed ID: 15007094
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Toll-like receptor-induced innate immune responses in non-parenchymal liver cells are cell type-specific.
    Wu J; Meng Z; Jiang M; Zhang E; Trippler M; Broering R; Bucchi A; Krux F; Dittmer U; Yang D; Roggendorf M; Gerken G; Lu M; Schlaak JF
    Immunology; 2010 Mar; 129(3):363-74. PubMed ID: 19922426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combining toll-like receptor agonists with immune checkpoint blockade affects antitumor vaccine efficacy.
    Jeon D; Hill E; Moseman JE; McNeel DG
    J Immunother Cancer; 2024 May; 12(5):. PubMed ID: 38702146
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Squamous cell carcinomas escape immune surveillance via inducing chronic activation and exhaustion of CD8+ T Cells co-expressing PD-1 and LAG-3 inhibitory receptors.
    Mishra AK; Kadoishi T; Wang X; Driver E; Chen Z; Wang XJ; Wang JH
    Oncotarget; 2016 Dec; 7(49):81341-81356. PubMed ID: 27835902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 Blockade Unleashes Effector Potential of Both High- and Low-Affinity Tumor-Infiltrating T Cells.
    Martínez-Usatorre A; Donda A; Zehn D; Romero P
    J Immunol; 2018 Jul; 201(2):792-803. PubMed ID: 29875150
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of Sunitinib and PD-L1 Blockade Enhances Anticancer Efficacy of TLR7/8 Agonist-Based Nanovaccine.
    Kim H; Khanna V; Kucaba TA; Zhang W; Ferguson DM; Griffith TS; Panyam J
    Mol Pharm; 2019 Mar; 16(3):1200-1210. PubMed ID: 30620878
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8
    Zahm CD; Colluru VT; McNeel DG
    Cancer Immunol Res; 2017 Aug; 5(8):630-641. PubMed ID: 28634215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TLR-9 signaling and TCR stimulation co-regulate CD8(+) T cell-associated PD-1 expression.
    Wong RM; Smith KA; Tam VL; Pagarigan RR; Meisenburg BL; Quach AM; Carrillo MA; Qiu Z; Bot AI
    Immunol Lett; 2009 Dec; 127(1):60-7. PubMed ID: 19751765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TLR activation excludes circulating naive CD8+ T cells from gut-associated lymphoid organs in mice.
    Heidegger S; Kirchner SK; Stephan N; Bohn B; Suhartha N; Hotz C; Anz D; Sandholzer N; Stecher B; Rüssmann H; Endres S; Bourquin C
    J Immunol; 2013 May; 190(10):5313-20. PubMed ID: 23589622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells.
    Lichtenegger FS; Rothe M; Schnorfeil FM; Deiser K; Krupka C; Augsberger C; Schlüter M; Neitz J; Subklewe M
    Front Immunol; 2018; 9():385. PubMed ID: 29535740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of PD-1 and LAG-3 Immune Checkpoints Combined with Vaccination Restores the Function of Antiviral Tissue-Resident CD8
    Roy S; Coulon PG; Prakash S; Srivastava R; Geertsema R; Dhanushkodi N; Lam C; Nguyen V; Gorospe E; Nguyen AM; Salazar S; Alomari NI; Warsi WR; BenMohamed L
    J Virol; 2019 Sep; 93(18):. PubMed ID: 31217250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alloreactive CD8 T cells rescued from apoptosis during co-stimulation blockade by Toll-like receptor stimulation remain susceptible to Fas-induced cell death.
    Priyadharshini B; Thornley TB; Daniels KA; Cuthbert A; Welsh RM; Greiner DL; Brehm MA
    Immunology; 2013 Apr; 138(4):322-32. PubMed ID: 23190301
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
    Prins RM; Craft N; Bruhn KW; Khan-Farooqi H; Koya RC; Stripecke R; Miller JF; Liau LM
    J Immunol; 2006 Jan; 176(1):157-64. PubMed ID: 16365406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.